Improving hospital surface disinfection to prevent infections
Clinical Ecosystem Surfaces for Improved Disinfection Outcomes and the Prevention of HAI Transmission
This study is working on a new way to make hospital surfaces safer by adding a special copper ingredient to paints and coatings, which will help kill germs and lower the chances of infections for patients.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Iasis Molecular Sciences, INC NIH-funded |
| Lab location | 1 site (Spokane, United States) |
| Project ID | NIH-10921313 on NIH RePORTER |
What this research studies
This research focuses on developing new methods for disinfecting surfaces in hospitals to reduce the transmission of healthcare-associated infections (HAIs). It aims to create a novel organometallic copper additive that can be incorporated into paints and coatings used on clinical surfaces. The effectiveness of these new formulations will be tested against various pathogens, including bacteria, viruses, and fungi. By improving the disinfection of surfaces, the research seeks to enhance patient safety and reduce infection rates in healthcare settings.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients receiving care in hospital settings where the risk of HAIs is prevalent.
Not a fit: Patients who are not hospitalized or those receiving care in outpatient settings may not benefit directly from this research.
Why it matters
Potential benefit: If successful, this research could significantly lower the rates of healthcare-associated infections, leading to better patient outcomes and reduced healthcare costs.
How similar studies have performed: Previous research has shown promise in using self-disinfecting surfaces to reduce infection rates, indicating that this approach could be effective.
Where this research is happening
Spokane, United States
- Iasis Molecular Sciences, INC — Spokane, United States (Active)
Researchers
- Principal investigator: Vachon, David John — Iasis Molecular Sciences, INC
- Study coordinator: Vachon, David John
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.